FindTrial
Sign In

To study the effectiveness in reducing spasticity of the two drugs, baclofen and tolperisone in children suffering from spastic cerebral palsy

Comparative study of clinical efficacy of TolperisonevsBaclofen in treating spasticity in children with Cerebral palsy:A 1year randomised controlled trial at KLES Dr Prabhakar Kore Charitable Hospital, Belgaum.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/12/022585
Enrollment
60
Registered
2019-12-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F82- Specific developmental disorder ofmotor function

Interventions

Intervention1: Tolperisone: 2 group of random sample is given tolperisone and followed for 3 months Tolperisone -2.5mg/kg/day in three divided doses for 3months Control Intervention1: Baclofen: Total

Sponsors

Jawaharlal Nehru medical College Belgaum
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Newly diagnosed spastic cerebral palsy

Exclusion criteria

Exclusion criteria: Subjects previously treated for spasticity associated with cerebral palsy

Design outcomes

Primary

MeasureTime frame
Compare clinical efficacy of tolperisone vs baclofenTimepoint: Efficacy is compared at the end of 3 months—

Secondary

MeasureTime frame
To know the side effects between the baclofen and tolperisoneTimepoint: 3months—

Countries

India

Contacts

Public ContactDr Deepthi S M

Jawaharlal Nehru Medical college, Belgaum

drdeepthi525@gmail.com8495052607

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026